Published in Oncogene on August 14, 2003
Human telomere, oncogenic promoter and 5'-UTR G-quadruplexes: diverse higher order DNA and RNA targets for cancer therapeutics. Nucleic Acids Res (2007) 3.49
DNA secondary structures: stability and function of G-quadruplex structures. Nat Rev Genet (2012) 3.15
G-quadruplex nucleic acids as therapeutic targets. Curr Opin Chem Biol (2009) 1.74
Preferential binding of a G-quadruplex ligand to human chromosome ends. Nucleic Acids Res (2005) 1.53
Structural insights into G-quadruplexes: towards new anticancer drugs. Future Med Chem (2010) 1.44
Formation of a unique end-to-end stacked pair of G-quadruplexes in the hTERT core promoter with implications for inhibition of telomerase by G-quadruplex-interactive ligands. J Am Chem Soc (2009) 1.42
Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb. Clin Cancer Res (2012) 1.17
Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia (2008) 1.10
Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo. Clin Cancer Res (2008) 1.04
Defining the mode, energetics and specificity with which a macrocyclic hexaoxazole binds to human telomeric G-quadruplex DNA. Nucleic Acids Res (2007) 1.02
Strategies targeting telomerase inhibition. Mol Biotechnol (2008) 0.94
Insights into the biomedical effects of carboxylated single-wall carbon nanotubes on telomerase and telomeres. Nat Commun (2012) 0.91
Targeting human telomeric G-quadruplex DNA with oxazole-containing macrocyclic compounds. Biochimie (2008) 0.91
Targeting homologous recombination and telomerase in Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth. Oncogene (2013) 0.89
G-quadruplexes: from guanine gels to chemotherapeutics. Mol Biotechnol (2011) 0.87
A dual-site simultaneous binding mode in the interaction between parallel-stranded G-quadruplex [d(TGGGGT)]4 and cyanine dye 2,2'-diethyl-9-methyl-selenacarbocyanine bromide. Nucleic Acids Res (2012) 0.86
Telomere biology: Rationale for diagnostics and therapeutics in cancer. RNA Biol (2015) 0.86
Rad51 and DNA-PKcs are involved in the generation of specific telomere aberrations induced by the quadruplex ligand 360A that impair mitotic cell progression and lead to cell death. Cell Mol Life Sci (2011) 0.85
G-Quadruplex binding enantiomers show chiral selective interactions with human telomere. Nucleic Acids Res (2014) 0.85
DNA damage signaling induced by the G-quadruplex ligand 12459 is modulated by PPM1D/WIP1 phosphatase. Nucleic Acids Res (2013) 0.85
Abnormal growth factor/cytokine network in gastric cancer. Cancer Microenviron (2008) 0.84
Overexpression of Bcl-2 is associated with apoptotic resistance to the G-quadruplex ligand 12459 but is not sufficient to confer resistance to long-term senescence. Nucleic Acids Res (2005) 0.83
Therapeutic targeting of replicative immortality. Semin Cancer Biol (2015) 0.83
Telomere and Telomerase Therapeutics in Cancer. Genes (Basel) (2016) 0.81
Crystal structure of a DNA/Ba2+ G-quadruplex containing a water-mediated C-tetrad. Nucleic Acids Res (2014) 0.80
A preclinical mouse model of glioma with an alternative mechanism of telomere maintenance (ALT). Int J Cancer (2014) 0.80
Targeting human telomerase for cancer therapeutics. Cytotechnology (2004) 0.79
Targeting the telomere and shelterin complex for cancer therapy: current views and future perspectives. J Cell Mol Med (2011) 0.79
c-Myc quadruplex-forming sequence Pu-27 induces extensive damage in both telomeric and nontelomeric regions of DNA. J Biol Chem (2014) 0.78
Cation involvement in telomestatin binding to g-quadruplex DNA. J Nucleic Acids (2010) 0.77
Induction of senescence in cancer cells by the G-quadruplex stabilizer, BMVC4, is independent of its telomerase inhibitory activity. Br J Pharmacol (2012) 0.77
Mechanism of the antiproliferative activity of some naphthalene diimide G-quadruplex ligands. Mol Pharmacol (2012) 0.76
New prospects for targeting telomerase beyond the telomere. Nat Rev Cancer (2016) 0.76
Effects of Replication and Transcription on DNA Structure-Related Genetic Instability. Genes (Basel) (2017) 0.76
Telomere targeting with a novel G-quadruplex-interactive ligand BRACO-19 induces T-loop disassembly and telomerase displacement in human glioblastoma cells. Oncotarget (2016) 0.75
A small molecule inhibitor of Pot1 binding to telomeric DNA. Biochemistry (2012) 0.75
p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell (2009) 4.30
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol (2012) 3.88
Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One (2009) 2.55
Genetic variants in C5 and poor response to eculizumab. N Engl J Med (2014) 1.91
Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex. J Am Chem Soc (2002) 1.82
Carotid intima-media thickness and plaque characteristics as a risk factor for stroke in Japanese elderly men. Stroke (2004) 1.79
Telomestatin-induced telomere uncapping is modulated by POT1 through G-overhang extension in HT1080 human tumor cells. J Biol Chem (2006) 1.74
Chronic kidney disease and drinking status in relation to risks of stroke and its subtypes: the Circulatory Risk in Communities Study (CIRCS). Stroke (2011) 1.63
Pulmonary alveolar proteinosis as a terminal complication in myelodysplastic syndromes: a report of four cases detected on autopsy. Leuk Res (2002) 1.60
Effects of habitual alcohol intake on ambulatory blood pressure, heart rate, and its variability among Japanese men. Hypertension (2008) 1.60
Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells. Mol Cancer Ther (2003) 1.60
Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood (2012) 1.56
Chemical genomics identifies the unfolded protein response as a target for selective cancer cell killing during glucose deprivation. Cancer Res (2009) 1.53
Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res (2010) 1.53
Chlamydia psittaci in ocular adnexal lymphoma: Japanese experience. Leuk Res (2006) 1.44
Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia? Leuk Res (2012) 1.44
Cost-effectiveness and budget impact analyses of a long-term hypertension detection and control program for stroke prevention. J Hypertens (2012) 1.44
Determination of T-cell receptors of clonal CD8-positive T-cells in myelodysplastic syndrome with erythroid hypoplasia. Leuk Res (2003) 1.43
Metabolic syndrome and the risk of ischemic heart disease and stroke among Japanese men and women. Stroke (2007) 1.43
Multiple lipoma with hyperlipidemia in a multiple myeloma patient treated with bortezomib/dexamethazone. Leuk Res (2009) 1.42
Monoclonal constitution of neutrophils detected by PCR-based human androgen receptor gene assay in a subset of idiopathic thrombocytopenic purpura patients. Leuk Res (2002) 1.41
Design and synthesis of an expanded porphyrin that has selectivity for the c-MYC G-quadruplex structure. J Am Chem Soc (2005) 1.40
Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J Biol Chem (2013) 1.40
Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol (2015) 1.39
Methylation of p15(INK4b) and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia. Leuk Res (2005) 1.33
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica (2011) 1.32
Reevaluation of telomerase inhibition by quadruplex ligands and their mechanisms of action. Proc Natl Acad Sci U S A (2007) 1.29
Interaction of telomestatin with the telomeric single-strand overhang. J Biol Chem (2004) 1.27
Improvement in Japanese clinical laboratory measurements of total cholesterol and HDL-cholesterol by the US Cholesterol Reference Method Laboratory Network. J Atheroscler Thromb (2003) 1.26
Enhancement of intracellular signaling associated with hematopoietic progenitor cell survival in response to SDF-1/CXCL12 in synergy with other cytokines. Blood (2002) 1.26
Mammalian DNA2 helicase/nuclease cleaves G-quadruplex DNA and is required for telomere integrity. EMBO J (2013) 1.25
Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med (2013) 1.23
Fat and protein intakes and risk of intraparenchymal hemorrhage among middle-aged Japanese. Am J Epidemiol (2003) 1.19
Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma. PLoS One (2011) 1.15
The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior. Cell Cycle (2009) 1.13
Linoleic acid, other fatty acids, and the risk of stroke. Stroke (2002) 1.12
The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci (2009) 1.12
Trends in the incidence of coronary heart disease and stroke and their risk factors in Japan, 1964 to 2003: the Akita-Osaka study. J Am Coll Cardiol (2008) 1.12
Macrocyclic and helical oligoamides as a new class of G-quadruplex ligands. J Am Chem Soc (2007) 1.10
ELF4/MEF activates MDM2 expression and blocks oncogene-induced p16 activation to promote transformation. Mol Cell Biol (2009) 1.09
Age-related decrease of miRNA-92a levels in human CD8+ T-cells correlates with a reduction of naïve T lymphocytes. Immun Ageing (2011) 1.09
Trends for blood pressure and its contribution to stroke incidence in the middle-aged Japanese population: the Circulatory Risk in Communities Study (CIRCS). Stroke (2009) 1.07
Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus. Sci Signal (2012) 1.06
Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese. Circulation (2004) 1.06
Vitamin K2 induces autophagy and apoptosis simultaneously in leukemia cells. Autophagy (2008) 1.03
Usual alcohol consumption and arterial oxygen desaturation during sleep. JAMA (2004) 1.03
Trends in the incidence of coronary heart disease and stroke and the prevalence of cardiovascular risk factors among Japanese men from 1963 to 1994. Am J Med (2002) 1.03
Proportions of stroke subtypes among men and women > or =40 years of age in an urban Japanese city in 1992, 1997, and 2002. Stroke (2006) 1.03
Fanconi anemia group J mutation abolishes its DNA repair function by uncoupling DNA translocation from helicase activity or disruption of protein-DNA complexes. Blood (2010) 1.02
The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations. Blood (2011) 1.02
Expression profile of a gamma-deletion variant of the human telomerase reverse transcriptase gene. Neoplasia (2003) 1.01
Telomeres and telomerase in hematologic neoplasia. Oncogene (2002) 1.01
Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a. BMC Res Notes (2010) 1.00
Detection of low allele burden of JAK2 exon 12 mutations using TA-cloning in patients with erythrocytosis. Jpn J Clin Oncol (2009) 0.99
Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis. Stem Cells Dev (2007) 0.97
Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes. Int J Hematol (2008) 0.96
Immunosuppressive treatments for myelodysplastic syndromes. Leuk Lymphoma (2003) 0.96
Establishment of long-term monitoring system for blood chemistry data by the national health and nutrition survey in Japan. J Atheroscler Thromb (2008) 0.95
Molecular characterization of the recurrent unbalanced translocation der(1;7)(q10;p10). Blood (2003) 0.94
Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia. Leuk Res (2009) 0.94
Stromal-cell-derived factor-1/CXCL12-induced chemotaxis of a T cell line involves intracellular signaling through Cbl and Cbl-b and their regulation by Src kinases and CD45. Blood Cells Mol Dis (2006) 0.94
Novel in vitro protein fragment complementation assay applicable to high-throughput screening in a 1536-well format. J Biomol Screen (2009) 0.94
Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Sci (2013) 0.93
Cyclin C regulates human hematopoietic stem/progenitor cell quiescence. Stem Cells (2010) 0.93
Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. Int J Hematol (2011) 0.93
Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells. Blood (2013) 0.93
Ankle-arm blood pressure index and cardiovascular risk factors in elderly Japanese men. Hypertens Res (2003) 0.92
Nerve growth factor attenuates 2-deoxy-d-glucose-triggered endoplasmic reticulum stress-mediated apoptosis via enhanced expression of GRP78. Neurosci Res (2009) 0.92
BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Clin Cancer Res (2003) 0.92
Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib. Br J Haematol (2011) 0.92
Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol (2011) 0.92
Phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan. Cancer Sci (2012) 0.92
Prospective study of major and minor ST-T abnormalities and risk of stroke among Japanese. Stroke (2003) 0.92
Relations between protein intake and blood pressure in Japanese men and women: the Circulatory Risk in Communities Study (CIRCS). Am J Clin Nutr (2009) 0.92
Alkaline phosphatase and risk of stroke among Japanese: the Circulatory Risk in Communities Study (CIRCS). J Stroke Cerebrovasc Dis (2012) 0.91
Relationships of craniofacial morphology and body mass index with sleep-disordered breathing in Japanese men. Laryngoscope (2004) 0.90
Asian variant of intravascular lymphoma: aspects of diagnosis and the role of rituximab. Intern Med (2007) 0.90
Nocturnal intermittent hypoxia and metabolic syndrome; the effect of being overweight: the CIRCS study. J Atheroscler Thromb (2010) 0.90
Streptomyces tateyamensis sp. nov., Streptomyces marinus sp. nov. and Streptomyces haliclonae sp. nov., isolated from the marine sponge Haliclona sp. Int J Syst Evol Microbiol (2010) 0.90